Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

In PwP presenting with LDDCI-associated MC, CSFLI represents an effective alternative that maintains dopaminergic efficacy while bypassing the gastrointestinal tract. Early recognition and timely switching to parenteral levodopa formulations may prevent prolonged symptoms and complications of MC in PwP. Microscopic colitis, a rare adverse effect of LDDCI therapy, may resolve completely with CSFLI.